Vanguard Plus 7, süstelahuse lüofilisaat ja lahusti koertele

Authorised

- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
- Canine parvovirus, strain NL-35-D, Live
- Canine parainfluenza virus, strain NL-CPI-5, Live
- Canine adenovirus 2, strain Manhattan, Live
- Canine distemper virus, strain N-CDV, Live

Product identification

Medicine name:
Vanguard Plus 7, süstelahuse lüofilisaat ja lahusti koertele

Active substance:
Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated

Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated

Canine parvovirus, strain NL-35-D, Live

Canine parainfluenza virus, strain NL-CPI-5, Live

Canine adenovirus 2, strain Manhattan, Live

Canine distemper virus, strain N-CDV, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
40.00 Hamster protective Dose 80 % (Ph. Eur. Monograph) / 1.00 dose

Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
40.00 Hamster protective Dose 80 % (Ph. Eur. Monograph) / 1.00 dose

Canine parvovirus, strain NL-35-D, Live
10000000.00 cell culture infective dose 50 / 1.00 dose

Canine parainfluenza virus, strain NL-CPI-5, Live
1000000.00 cell culture infective dose 50 / 1.00 dose

Canine adenovirus 2, strain Manhattan, Live
1585.00 cell culture infective dose 50 / 1.00 dose

Canine distemper virus, strain N-CDV, Live
1000.00 cell culture infective dose 50 / 1.00 dose

Pharmaceutical form:
Lyophilisate and solvent for solution for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AI02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:

Estonia

Package description:
Available only in Estonian

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Zoetis Belgium

Marketing authorisation date:
27/04/2004

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:
State Agency Of Medicines

Authorisation number:
1254

Date of authorisation status change:
27/04/2004

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
